The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Cancer Immunotherapy: A Treatment for the Masses
Abstract
Cancer immunotherapy attempts to harness the exquisite power and specificity of the immune system for the treatment of malignancy. Although cancer cells are less immunogenic than pathogens, the immune system is clearly capable of recognizing and eliminating tumor cells. However, tumors frequently interfere with the development and function of immune responses. Thus, the challenge for immunotherapy is to use advances in cellular and molecular immunology to develop strategies that effectively and safely augment antitumor responses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Takeda, K., Kaisho, T., & Akira, S. (2003) · Annual Review of Immunology · doi:10.1146/annurev.immunol.21.120601.141126 · Cited by 6,143
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
Zhang, L., Conejo-Garcia, J. R., Katsaros, D., Gimotty, P. A., Massobrio, M., Regnani, G., Makrigiannakis, A., Gray, H., Schlienger, K., Liebman, M. N., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020177 · Cited by 3,397
The Three Es of Cancer Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104803 · Cited by 3,072
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896
Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells
Nestle, F. O., Alijagic, S., Gilliet, M., Sun, Y., Grabbe, S., Dummer, R., Burg, G., & Schadendorf, D. (1998) · Nature Medicine · doi:10.1038/nm0398-328 · Cited by 2,862
Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes
Dudley, M. E., Wunderlich, J. R., Robbins, P. F., Yang, J. C., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Sherry, R., Restifo, N. P., Hubicki, A. M., et al. (2002) · Science · doi:10.1126/science.1076514 · Cited by 2,823
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768
Gabrilovich, D. I., Chen, H. L., Girgis, K. R., Cunningham, H. T., Meny, G. M., Nadaf, S., Kavanaugh, D., & Carbone, D. P. (1996) · Nature Medicine · doi:10.1038/nm1096-1096 · Cited by 1,977
Rosenberg, S. A., Yang, J. C., Schwartzentruber, D. J., Hwu, P., Marincola, F. M., Topalian, S. L., Restifo, N. P., Dudley, M. E., Schwarz, S. L., Spiess, P. J., et al. (1998) · Nature Medicine · doi:10.1038/nm0398-321 · Cited by 1,784
Walter, E. A., Greenberg, P. D., Gilbert, M. J., Finch, R. J., Watanabe, K. S., Thomas, E. D., & Riddell, S. R. (1995) · New England Journal of Medicine · doi:10.1056/nejm199510193331603 · Cited by 1,771
Self-citationTumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation
Groh, V., Wu, J., Yee, C., & Spies, T. (2002) · Nature · doi:10.1038/nature01112 · Cited by 1,592
Phan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533209100 · Cited by 1,575
Shimizu, J., Yamazaki, S., & Sakaguchi, S. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.10.5211 · Cited by 1,491
Yee, C., Thompson, J. A., Byrd, D., Riddell, S. R., Roche, P., Celis, E., & Greenberg, P. D. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.242600099 · Cited by 1,206
Self-citationMarincola, F. M., Jaffee, E. M., Hicklin, D. J., & Ferrone, S. (1999) · Advances in Immunology · doi:10.1016/s0065-2776(08)60911-6 · Cited by 1,174
Role of Bone Marrow-Derived Cells in Presenting MHC Class I-Restricted Tumor Antigens
Huang, A. Y. C., Golumbek, P., Ahmadzadeh, M., Jaffee, E., Pardoll, D., & Levitsky, H. (1994) · Science · doi:10.1126/science.7513904 · Cited by 1,160
Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells
Wang, T., Niu, G., Kortylewski, M., Burdelya, L., Shain, K., Zhang, S., Bhattacharya, R., Gabrilovich, D., Heller, R., Coppola, D., et al. (2004) · Nature Medicine · doi:10.1038/nm976 · Cited by 1,155
Rooney, C. M., Smith, C. A., Ng, C. Y. C., Loftin, S. K., Sixbey, J. W., Gan, Y., Srivastava, D.-K., Bowman, L. C., Krance, R. A., Brenner, M. K., et al. (1998) · Blood · doi:10.1182/blood.v92.5.1549 · Cited by 1,135
Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients
Lee, P. P., Yee, C., Savage, P. A., Fong, L., Brockstedt, D., Weber, J. S., Johnson, D., Swetter, S., Thompson, J., Greenberg, P. D., et al. (1999) · Nature Medicine · doi:10.1038/9525 · Cited by 1,113
Self-citationSutmuller, R. P. M., van Duivenvoorde, L. M., van Elsas, A., Schumacher, T. N. M., Wildenberg, M. E., Allison, J. P., Toes, R. E. M., Offringa, R., & Melief, C. J. M. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.6.823 · Cited by 1,008
Hodi, F. S., Mihm, M. C., Soiffer, R. J., Haluska, F. G., Butler, M., Seiden, M. V., Davis, T., Henry-Spires, R., MacRae, S., Willman, A., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0830997100 · Cited by 1,006
Childs, R., Chernoff, A., Contentin, N., Bahceci, E., Schrump, D., Leitman, S., Read, E. J., Tisdale, J., Dunbar, C., Linehan, W. M., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009143431101 · Cited by 998
Improving the efficacy of antibody-based cancer therapies
Carter, P. (2001) · Nature Reviews Cancer · doi:10.1038/35101072 · Cited by 833
Gorelik, L., & Flavell, R. A. (2001) · Nature Medicine · doi:10.1038/nm1001-1118 · Cited by 770
Induction of antigen-specific T cell anergy: An early event in the course of tumor progression
Staveley-O’Carroll, K., Sotomayor, E., Montgomery, J., Borrello, I., Hwang, L., Fein, S., Pardoll, D., & Levitsky, H. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.3.1178 · Cited by 704
Woo, E. Y., Yeh, H., Chu, C. S., Schlienger, K., Carroll, R. G., Riley, J. L., Kaiser, L. R., & June, C. H. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.9.4272 · Cited by 696
Brentjens, R. J., Latouche, J.-B., Santos, E., Marti, F., Gong, M. C., Lyddane, C., King, P. D., Larson, S., Weiss, M., Rivière, I., et al. (2003) · Nature Medicine · doi:10.1038/nm827 · Cited by 669
Rosenberg, S. A., Lotze, M. T., Yang, J. C., Topalian, S. L., Chang, A. E., Schwartzentruber, D. J., Aebersold, P., Leitman, S., Linehan, W. M., Seipp, C. A., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.8.622 · Cited by 639
γδ T cells for immune therapy of patients with lymphoid malignancies
Wilhelm, M., Kunzmann, V., Eckstein, S., Reimer, P., Weissinger, F., Ruediger, T., & Tony, H.-P. (2003) · Blood · doi:10.1182/blood-2002-12-3665 · Cited by 550
Timmerman, J. M., Czerwinski, D. K., Davis, T. A., Hsu, F. J., Benike, C., Hao, Z. M., Taidi, B., Rajapaksa, R., Caspar, C. B., Okada, C. Y., et al. (2002) · Blood · doi:10.1182/blood.v99.5.1517 · Cited by 545
Chemokines: agents for the immunotherapy of cancer?
Homey, B., Müller, A., & Zlotnik, A. (2002) · Nature Reviews Immunology · doi:10.1038/nri748 · Cited by 398
Nieda, M., Okai, M., Tazbirkova, A., Lin, H., Yamaura, A., Ide, K., Abraham, R., Juji, T., Macfarlane, D. J., & Nicol, A. J. (2004) · Blood · doi:10.1182/blood-2003-04-1155 · Cited by 361
Spinning molecular immunology into successful immunotherapy
Pardoll, D. M. (2002) · Nature Reviews Immunology · doi:10.1038/nri774 · Cited by 360
Tumor Development after 3-Methylcholanthrene in Immunologically Deficient Athymic-Nude Mice
Stutman, O. (1974) · Science · doi:10.1126/science.183.4124.534 · Cited by 356
van Elsas, A., Sutmuller, R. P. M., Hurwitz, A. A., Ziskin, J., Villasenor, J., Medema, J.-P., Overwijk, W. W., Restifo, N. P., Melief, C. J. M., Offringa, R., et al. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.4.481 · Cited by 309
Innate Immune Surveillance of Spontaneous B Cell Lymphomas by Natural Killer Cells and γδ T Cells
Street, S. E. A., Hayakawa, Y., Zhan, Y., Lew, A. M., MacGregor, D., Jamieson, A. M., Diefenbach, A., Yagita, H., Godfrey, D. I., & Smyth, M. J. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20031981 · Cited by 264
Monoclonal Antibody Therapy for Cancer
Mehren, M. V., Adams, G. P., & Weiner, L. M. (2003) · Annual Review of Medicine · doi:10.1146/annurev.med.54.101601.152442 · Cited by 191
Adoptive immunotherapy: Engineering T cell responses as biologic weapons for tumor mass destruction
Ho, W., Blattman, J. N., Dossett, M. L., Yee, C., & Greenberg, P. D. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00113-2 · Cited by 157
Self-citationCheng, L. E., Öhlén, C., Nelson, B. H., & Greenberg, P. D. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.052676899 · Cited by 128
Self-citationEngelhard, V. H., Bullock, T. N. J., Colella, T. A., Sheasley-O’Neill, S. L., & Mullins, D. W. (2002) · Immunological Reviews · doi:10.1034/j.1600-065x.2002.18812.x · Cited by 128
Karanikas, V., Lurquin, C., Colau, D., van Baren, N., Smet, C. D., Lethé, B., Connerotte, T., Corbière, V., Demoitié, M., Líénard, D., et al. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.9.4898 · Cited by 111
Marroquin, C. E., Westwood, J. A., Lapointe, R., Mixon, A., Wunderlich, J. R., Caron, D. A., Rosenberg, S. A., & Hwu, P. (2002) · Journal of Immunotherapy · doi:10.1097/00002371-200205000-00011 · Cited by 70
Cited by
STATs in cancer inflammation and immunity: a leading role for STAT3
Yu, H., Pardoll, D., & Jove, R. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2734 · Cited by 4,383
Cancer regression in patients after transfer of genetically engineered lymphocytes
Morgan, R. A., Dudley, M. E., Wunderlich, J. R., Hughes, M. S., Yang, J. C., Sherry, R. M., Royal, R. E., Topalian, S. L., Kammula, U. S., Restifo, N. P., et al. (2006) · Science · doi:10.1126/science.1129003 · Cited by 2,603
Taking dendritic cells into medicine
Steinman, R. M., & Banchereau, J. (2007) · Nature · doi:10.1038/nature06175 · Cited by 2,127
Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment
Yu, H., Kortylewski, M., & Pardoll, D. (2007) · Nature Reviews Immunology · doi:10.1038/nri1995 · Cited by 1,804
Physical approaches to biomaterial design
Mitragotri, S., & Lahann, J. (2009) · Nature Materials · doi:10.1038/nmat2344 · Cited by 1,445
Metadata
- Authors
- Blattman, J. N., & Greenberg, P. D.
- Venue
- Science
- Published
- 2004-07-09
- Volume
- 305
- Issue
- 5681
- Pages
- 200-205
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2020920166
- Cited by
- 612
- References
- 42
- FWCI
- 26.73
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.